
SRRK Stock Forecast & Price Target
SRRK Analyst Ratings
Bulls say
Scholar Rock Holding is facing potential risks such as the failure of its pipeline candidates to show efficacy and competition from alternative approaches. Additionally, the broad adoption of gene therapies in the targeted patient population could limit the company's growth potential. However, if the Catalent site is replaced and the full data/CMC package is approved in a timely manner, and if regulatory hurdles are successfully addressed, this could lead to increased investor confidence and a positive outlook for the company's stock.
Bears say
Scholar Rock Holding is expected to face challenges in the short term, due to the recent classification of its second fill-finish facility by the FDA, but its strong pipeline of therapies for rare neuromuscular diseases remains a long-term growth driver. Despite the potential delays in obtaining approvals for its therapies in both the US and EU markets, the company's proactive approach of having a two-site redundancy and progress in the regulatory review of the second facility, shows strong management capabilities and a commitment to its pipeline. However, investors should remain cautious and monitor any updates on the regulatory timeline and potential impact on the company's commercial launch and market potential.
This aggregate rating is based on analysts' research of Scholar Rock Holding Corp and is not a guaranteed prediction by Public.com or investment advice.
SRRK Analyst Forecast & Price Prediction
Start investing in SRRK
Order type
Buy in
Order amount
Est. shares
0 shares